ADMA Biologics, Inc.
ADMA
$8.47
-15.97%
ADMA Biologics, Inc. is a fully integrated commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty plasma-derived biologics, primarily for immunodeficient patients at risk of infection. The company operates as a niche player in the plasma therapeutics industry, distinguishing itself through its end-to-end control of the supply chain, from plasma collection through manufacturing. The current investor narrative is dominated by significant uncertainty and negative sentiment following a securities fraud investigation announced in late March 2026, which alleges channel stuffing and inflated revenue, leading to a precipitous stock decline and casting doubt on the company's recent financial performance and governance.…
ADMA
ADMA Biologics, Inc.
$8.47
Related headlines
ADMA 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on ADMA Biologics, Inc.'s 12-month outlook, with a consensus price target around $11.01 and implied upside of +30.0% versus the current price.
Average Target
$11.01
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$7 - $11
Analyst target range
Analyst coverage for ADMA appears limited, with data indicating only one analyst providing estimates for revenue and EPS, and no consensus price target or recommendation distribution available in the provided dataset. The single analyst's estimates project revenue of approximately $1.26 billion and EPS of $2.295, but the lack of a broader consensus and price targets suggests insufficient institutional analyst coverage. This limited coverage, combined with the recent fraud investigation, creates an environment of high uncertainty and inefficient price discovery; the stock's future path will likely be driven more by legal developments and potential regulatory actions than by analyst revisions, making it a highly speculative situation for investors.
Bulls vs Bears: ADMA Investment Factors
The investment debate for ADMA is dominated by a stark conflict between strong reported fundamentals and a severe governance crisis. The bull case rests on impressive profitability metrics, consistent revenue growth, and a cheap forward valuation. However, the bear case, currently possessing stronger evidence, is anchored by an active securities fraud investigation that directly challenges the validity of those very fundamentals and has triggered a catastrophic loss of investor confidence. The single most important tension is the resolution of the fraud allegations: if disproven, the stock's deep undervaluation on forward earnings could drive a sharp rally; if confirmed, the reported financial strength evaporates, likely leading to further precipitous declines, restatements, and potential delisting.
Bullish
- Strong Profitability & Margin Expansion: Q4 2025 reported a net margin of 35.48% and a gross margin of 63.82%, up from 53.22% in Q1 2025. This demonstrates powerful operating leverage and pricing power in its core biologics business.
- Robust Revenue Growth Trajectory: Quarterly revenue grew consistently from $114.80M in Q1 2025 to $139.16M in Q4 2025, an 18.39% YoY increase for Q4. This indicates strong underlying demand for its plasma-derived products.
- Healthy Balance Sheet & Low Leverage: The company has a strong current ratio of 6.71 and a low debt-to-equity ratio of 0.167. This provides financial flexibility and resilience amidst the current crisis.
- Low Forward P/E Suggests Deep Value: The forward P/E ratio is 8.22x based on an analyst EPS estimate of $2.295. This is a very low multiple for a profitable biotech, implying the market is pricing in severe risk, creating potential upside if the company is exonerated.
Bearish
- Active Securities Fraud Investigation: The company is under investigation for alleged channel stuffing and inflated revenue, announced in late March 2026. This has caused the stock to plummet 25.96% in the past month and creates existential uncertainty over all reported financials.
- Severe Technical & Sentiment Breakdown: The stock is down 48.33% over the past year and 36.40% over 3 months, with a max drawdown of -66.18%. It shows a -33.32 relative strength vs. the S&P 500 over the past month, indicating overwhelming company-specific distress.
- High Trailing P/E Amidst Crisis: The trailing P/E of 29.58x is elevated and sits above its level of 21.98x at the end of Q4 2025. This valuation is untenable given the fraud allegations and points to significant multiple contraction risk if the investigation confirms wrongdoing.
- Limited Analyst Coverage & High Uncertainty: Only one analyst provides estimates, with no consensus price target available. This lack of coverage and guidance exacerbates the environment of inefficient price discovery and high volatility driven by legal developments.
ADMA Technical Analysis
The stock is in a severe and sustained downtrend, characterized by a 1-year price decline of 48.33% and a 3-month drop of 36.40%. Trading at a current price of $11.01, it sits approximately 43% above its 52-week low of $7.21 but remains 57% below its 52-week high of $25.67, indicating it is deeply depressed but not at the absolute lows, suggesting potential for further downside or a volatile bottoming process. Recent momentum is decisively negative and accelerating, with the stock down 25.96% over the past month, a stark contrast to the S&P 500's 7.36% gain, resulting in a severe relative strength reading of -33.32; this divergence from the broader market highlights company-specific distress, primarily the fraud investigation, overwhelming any sector or market tailwinds. Key technical support is the 52-week low of $7.21, with resistance at the recent breakdown level near $15-$16; a decisive break below $7.21 would signal a complete loss of confidence and open the door to new lows, while a recovery above $16 would require a significant clearing of the negative overhang. The stock's beta of 0.82 suggests it has been less volatile than the market historically, but the recent collapse and a max drawdown of -66.18% indicate extreme idiosyncratic risk that standard beta fails to capture, demanding careful risk management.
Beta
0.82
0.82x market volatility
Max Drawdown
-66.2%
Largest decline past year
52-Week Range
$7-$23
Price range past year
Annual Return
-64.1%
Cumulative gain past year
| Period | ADMA Return | S&P 500 |
|---|---|---|
| 1m | -8.5% | +11.0% |
| 3m | -48.4% | +5.9% |
| 6m | -41.7% | +9.0% |
| 1y | -64.1% | +30.4% |
| ytd | -52.6% | +7.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ADMA Fundamental Analysis
Revenue growth has been robust but is now under a cloud of suspicion; the most recent quarterly revenue (Q4 2025) was $139.16 million, representing a solid 18.39% year-over-year increase, and sequential quarterly revenue throughout 2025 showed consistent growth from $114.80 million in Q1 to the Q4 figure. The company is profitable with strong and expanding margins; Q4 2025 net income was $49.38 million, yielding a net margin of 35.48%, while the gross margin for the quarter was an impressive 63.82%, up significantly from 53.22% in Q1 2025, demonstrating powerful operating leverage and pricing power in its core biologics manufacturing segment, though the fraud allegations question the sustainability of these figures. The balance sheet appears healthy with a strong current ratio of 6.71 and a low debt-to-equity ratio of 0.167, indicating ample liquidity and low financial leverage; trailing twelve-month free cash flow was $27.82 million, and return on equity was a high 30.78%, suggesting efficient use of shareholder capital, but the quality of these metrics is now suspect pending the investigation's outcome.
Quarterly Revenue
$139163000.0B
2025-12
Revenue YoY Growth
+0.18%
YoY Comparison
Gross Margin
+0.63%
Latest Quarter
Free Cash Flow
$27821000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ADMA Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 29.58x, while the forward PE is significantly lower at 8.22x, based on a forward EPS estimate of $2.295; this wide gap implies the market expects a substantial near-term earnings surge, but it also reflects deep skepticism about current reported profits given the fraud allegations. Compared to the Biotechnology industry, a trailing PE of 29.58x is difficult to contextualize without a specific industry average provided in the data, but the forward PE of 8.22x appears low for a biotech firm with reported high growth and margins, suggesting the market is pricing in either a dramatic earnings increase or, more likely, a high risk of financial restatements and reputational damage. Historically, the stock's own trailing PE has fluctuated wildly, from negative figures during loss-making periods to 21.98x at the end of Q4 2025; the current 29.58x is above that recent level but below peaks seen in early 2025 (e.g., 43.84x in Q1), placing it in the mid-to-upper range of its recent history, which seems untenable given the current crisis and points to potential multiple contraction if the investigation confirms wrongdoing.
PE
29.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -32x~79x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary risk is the potential for material financial restatements and legal liabilities stemming from the securities fraud investigation. If the allegations of channel stuffing and revenue inflation are substantiated, the company's reported 18.39% YoY revenue growth and 35.48% net margin for Q4 2025 could be significantly revised downward, invalidating the core investment thesis. Furthermore, while the balance sheet is currently strong (D/E of 0.167), legal fines, settlements, and operational disruption could rapidly consume cash and necessitate capital raises. The high trailing P/E of 29.58x leaves the stock vulnerable to severe multiple compression if earnings are restated lower.
Market & Competitive Risks: The stock faces extreme valuation compression risk, trading at a premium to its recent historical P/E while under a fraud cloud. Its beta of 0.82 understates the extreme idiosyncratic risk, as evidenced by the -66.18% max drawdown. The negative sentiment is so profound that the stock fell 25.96% in a month while the S&P 500 rose 7.36%, demonstrating complete decoupling from market tailwinds. Competitive and regulatory risks are secondary but heightened; the scandal damages its reputation with customers and could attract scrutiny from the FDA or other regulators, potentially impacting its plasma collection and manufacturing licenses.
Worst-Case Scenario: The worst-case scenario involves the fraud investigation confirming systemic accounting misconduct, leading to massive financial restatements, shareholder lawsuits, SEC fines, and a loss of key management. This could trigger a covenant breach on its debt (despite low current leverage), a collapse in customer and partner confidence, and a potential delisting threat from Nasdaq. In this scenario, the stock could re-test and break below its 52-week low of $7.21, representing a downside of approximately -34.5% from the current price of $11.01. A prolonged legal overhang and broken business model could see the stock trade toward liquidation value, implying a realistic loss potential of 50% or more from current levels.